HIGHLIGHTS
- who: Filippo Bellati et al. from the of Gynecology and, University of Rome, Italy have published the article: Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View, in the Journal: (JOURNAL)
- what: Although the combination of cetuximab, paclitaxel, and Endometrial Cancer with FGFR mutation Epithelial Carcinomas Bevacizumab FP-1039 Catumaxomab carboplatin was well tolerated in this patient population, this study showed that this combination therapy failed to demonstrate a prolongation of PFS when compared with historical data. Of this trial showed only modest activity with a response rate of 34.5% . Currently, the primary . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.